VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Trial details
- Registry ID
- NCT06264180
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as OPDUALAG; Opdualag
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]NCT06264180 | Replimune, Inc. | Phase 3 | Recruiting | 2030-09-30Estimated |
| IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)NCT06112314 | Immunocore Ltd | Phase 3 | Recruiting | 2027-10-16Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |